GPR84

Across TCGA pan-cancer cohorts, GPR84 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated GPR84 data layer compared with 22 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher GPR84 Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated GPR84 expression acts as an unfavorable survival marker, although some lineages such as SKCM and BRCA show a favorable association.

ACC, CESC, and LUSC are the cancer types where GPR84 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.046	0.753	<.001	36	view →
CESC	OS	Median	All	0.261	0.798	.018	6	view →
LUSC	OS	Median	II,III,IV	0.080	0.733	<.001	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	DFS	Median	II,III,IV	1.000	0.214	.014	4	view →
BRCA	OS	Median	All	0.927	0.924	.046	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

GPR84–ACC (DFS)

Open the ACC breakdown →